APA (7th ed.) Citation

JA, K., AV, M., J, F., LJ, M., E, P., JL, B., . . . A, A. (2017). Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias. Pharmacotherapy, 37(6), 673. https://doi.org/10.1002/phar.1932

Chicago Style (17th ed.) Citation

JA, Kaye, Margulis AV, Fortuny J, McQuay LJ, Plana E, Bartsch JL, Bui CL, Perez-Gutthann S, and Arana A. "Cancer Incidence After Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias." Pharmacotherapy 37, no. 6 (2017): 673. https://doi.org/10.1002/phar.1932.

MLA (9th ed.) Citation

JA, Kaye, et al. "Cancer Incidence After Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias." Pharmacotherapy, vol. 37, no. 6, 2017, p. 673, https://doi.org/10.1002/phar.1932.